Symbols / SLN Stock $7.84 -1.63% Silence Therapeutics plc
SLN (Stock) Chart
About
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Stock Fundamentals
Scroll to Statements| Market Cap | 370.31M | Enterprise Value | 1.04B | Income | -88.61M | Sales | 559.00K | Book/sh | 1.32 | Cash/sh | 0.60 |
| Dividend Yield | — | Payout | 0.00% | Employees | 88 | IPO | — | P/E | — | Forward P/E | -10.89 |
| PEG | — | P/S | 662.46 | P/B | 5.94 | P/C | — | EV/EBITDA | -12.78 | EV/Sales | 1868.35 |
| Quick Ratio | 8.06 | Current Ratio | 8.72 | Debt/Eq | 0.26 | LT Debt/Eq | — | EPS (ttm) | -1.89 | EPS next Y | -0.72 |
| EPS Growth | — | Revenue Growth | -99.90% | Earnings | 2026-05-07 | ROA | -30.79% | ROE | -90.27% | ROIC | — |
| Gross Margin | 61.54% | Oper. Margin | -371.50% | Profit Margin | 0.00% | Shs Outstand | 47.23M | Shs Float | 74.75M | Short Float | 4.91% |
| Short Ratio | 4.99 | Short Interest | — | 52W High | 8.40 | 52W Low | 3.08 | Beta | 1.33 | Avg Volume | 308.92K |
| Volume | 510.33K | Target Price | $32.80 | Recom | None | Prev Close | $7.97 | Price | $7.84 | Change | -1.63% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2025-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $35 |
| 2025-06-13 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2025-06-13 | main | Chardan Capital | Buy → Buy | $35 |
| 2025-05-09 | main | Goldman Sachs | Sell → Sell | $3 |
| 2025-05-09 | main | Morgan Stanley | Overweight → Overweight | $25 |
| 2025-05-09 | main | Chardan Capital | Buy → Buy | $35 |
| 2025-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2025-03-05 | main | Morgan Stanley | Overweight → Overweight | $45 |
| 2025-03-04 | main | BMO Capital | Outperform → Outperform | $25 |
| 2025-03-04 | main | Goldman Sachs | Sell → Sell | $4 |
| 2025-02-11 | init | Goldman Sachs | — → Sell | $6 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2025-01-29 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-12-10 | main | Chardan Capital | Buy → Buy | $55 |
| 2024-12-09 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $75 |
| 2024-11-14 | main | Chardan Capital | Buy → Buy | $55 |
News
RSS: Latest SLN news- Silence Therapeutics (SLN) soars 19.0%: Is further upside left in the stock? - MSN Wed, 22 Apr 2026 23
- With Silence Therapeutics Up 24%, Insider Buyers Count Their Returns - simplywall.st hu, 16 Apr 2026 10
- H.C. Wainwright Reaffirms Their Buy Rating on Silence Therapeutics (SLN) - The Globe and Mail Wed, 08 Apr 2026 07
- If You Invested $1,000 in Silence Therapeutics Plc (SLN) - Stock Titan Sun, 22 Mar 2026 09
- Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation - 富途牛牛 hu, 16 Apr 2026 10
- Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High? - Yahoo Finance hu, 05 Mar 2026 08
- Understanding Momentum Shifts in (SLN) - Stock Traders Daily Sun, 15 Mar 2026 19
- Silence Therapeutics: Divesiran Targets High-Burden PV (NASDAQ:SLN) - Seeking Alpha ue, 18 Nov 2025 08
- Revenues Working Against Silence Therapeutics plc's (NASDAQ:SLN) Share Price Following 27% Dive - simplywall.st hu, 05 Feb 2026 08
- Pipeline shifts and 2025 results at Silence Therapeutics (SLN) - Stock Titan hu, 05 Mar 2026 08
- Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN Sat, 04 Apr 2026 08
- Silence Therapeutics ADR share price | SLN - Hargreaves Lansdown Wed, 28 Jan 2026 17
- With 35% ownership, Silence Therapeutics plc (NASDAQ:SLN) insiders have a lot at stake - Yahoo Finance Sun, 21 Dec 2025 08
- Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation - simplywall.st Sat, 31 Jan 2026 08
- SLN Stock Quote Price and Forecast - CNN Wed, 01 Nov 2023 12
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.56
-98.71%
|
43.26
+36.71%
|
31.64
+46.12%
|
21.66
|
| Operating Revenue |
|
0.56
-98.71%
|
43.26
+36.71%
|
31.64
+46.12%
|
21.66
|
| Cost Of Revenue |
|
0.21
-98.18%
|
11.81
-8.21%
|
12.87
-4.43%
|
13.46
|
| Reconciled Cost Of Revenue |
|
0.21
-98.18%
|
11.81
-8.21%
|
12.87
-4.43%
|
13.46
|
| Gross Profit |
|
0.34
-98.91%
|
31.45
+67.49%
|
18.78
+129.20%
|
8.19
|
| Operating Expense |
|
90.10
-4.93%
|
94.77
+13.96%
|
83.16
+20.12%
|
69.23
|
| Research And Development |
|
67.75
-0.19%
|
67.88
+19.22%
|
56.94
+30.74%
|
43.55
|
| Selling General And Administration |
|
22.34
-16.89%
|
26.88
+2.52%
|
26.22
+2.10%
|
25.68
|
| General And Administrative Expense |
|
22.34
-16.89%
|
26.88
+2.52%
|
26.22
+2.10%
|
25.68
|
| Other Gand A |
|
22.34
-16.89%
|
26.88
+2.52%
|
26.22
+2.10%
|
25.68
|
| Other Operating Expenses |
|
—
|
-13.74
-14.96%
|
-11.95
-21.68%
|
-9.82
|
| Total Expenses |
|
90.31
-15.26%
|
106.58
+10.99%
|
96.03
+16.12%
|
82.69
|
| Operating Income |
|
-89.75
-41.75%
|
-63.32
+1.65%
|
-64.38
-5.48%
|
-61.04
|
| Total Operating Income As Reported |
|
-91.08
-43.84%
|
-63.32
+1.65%
|
-64.38
-5.48%
|
-61.04
|
| EBITDA |
|
-89.20
-42.20%
|
-62.73
+1.62%
|
-63.76
-5.49%
|
-60.44
|
| Normalized EBITDA |
|
-79.41
-25.30%
|
-63.37
-3.68%
|
-61.12
+1.00%
|
-61.74
|
| Reconciled Depreciation |
|
0.56
-6.41%
|
0.59
-4.51%
|
0.62
+4.19%
|
0.60
|
| EBIT |
|
-89.75
-41.75%
|
-63.32
+1.65%
|
-64.38
-5.48%
|
-61.04
|
| Total Unusual Items |
|
-9.79
-1615.63%
|
0.65
+124.46%
|
-2.64
-304.10%
|
1.29
|
| Total Unusual Items Excluding Goodwill |
|
-9.79
-1615.63%
|
0.65
+124.46%
|
-2.64
-304.10%
|
1.29
|
| Special Income Charges |
|
-1.32
|
0.00
|
—
|
—
|
| Restructuring And Mergern Acquisition |
|
1.32
|
0.00
|
—
|
—
|
| Net Income |
|
-88.61
-95.57%
|
-45.31
+16.45%
|
-54.23
-7.74%
|
-50.33
|
| Pretax Income |
|
-88.60
-99.26%
|
-44.46
+16.53%
|
-53.27
-7.30%
|
-49.65
|
| Net Non Operating Interest Income Expense |
|
3.48
-22.18%
|
4.47
+148.03%
|
1.80
+543.93%
|
0.28
|
| Interest Expense Non Operating |
|
—
|
—
|
0.04
-23.85%
|
0.06
|
| Net Interest Income |
|
3.48
-22.18%
|
4.47
+148.03%
|
1.80
+543.93%
|
0.28
|
| Interest Expense |
|
—
|
—
|
0.04
-23.85%
|
0.06
|
| Interest Income Non Operating |
|
3.48
-22.18%
|
4.47
+148.03%
|
1.80
+543.93%
|
0.28
|
| Interest Income |
|
3.48
-22.18%
|
4.47
+148.03%
|
1.80
+543.93%
|
0.28
|
| Other Income Expense |
|
-2.33
-116.19%
|
14.38
+54.52%
|
9.31
-16.25%
|
11.11
|
| Other Non Operating Income Expenses |
|
7.46
-45.67%
|
13.74
+14.96%
|
11.95
+21.68%
|
9.82
|
| Gain On Sale Of Security |
|
-8.47
-1410.68%
|
0.65
+124.46%
|
-2.64
-304.10%
|
1.29
|
| Tax Provision |
|
0.01
-98.70%
|
0.84
-11.61%
|
0.96
+38.95%
|
0.69
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+31.58%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-2.45
-1615.63%
|
0.16
+132.18%
|
-0.50
-304.10%
|
0.25
|
| Net Income Including Noncontrolling Interests |
|
-88.61
-95.57%
|
-45.31
+16.45%
|
-54.23
-7.74%
|
-50.33
|
| Net Income From Continuing Operation Net Minority Interest |
|
-88.61
-95.57%
|
-45.31
+16.45%
|
-54.23
-7.74%
|
-50.33
|
| Net Income From Continuing And Discontinued Operation |
|
-88.61
-95.57%
|
-45.31
+16.45%
|
-54.23
-7.74%
|
-50.33
|
| Net Income Continuous Operations |
|
-88.61
-95.57%
|
-45.31
+16.45%
|
-54.23
-7.74%
|
-50.33
|
| Normalized Income |
|
-81.27
-77.47%
|
-45.79
+12.09%
|
-52.09
-1.38%
|
-51.38
|
| Net Income Common Stockholders |
|
-88.61
-95.57%
|
-45.31
+16.45%
|
-54.23
-7.74%
|
-50.33
|
| Diluted EPS |
|
-1.89
-90.91%
|
-0.99
+32.65%
|
-1.47
+5.77%
|
-1.56
|
| Basic EPS |
|
-1.89
-90.91%
|
-0.99
+32.65%
|
-1.47
+5.77%
|
-1.56
|
| Basic Average Shares |
|
47.23
+2.12%
|
46.25
+24.69%
|
37.09
+15.21%
|
32.19
|
| Diluted Average Shares |
|
47.23
+2.12%
|
46.25
+24.69%
|
37.09
+15.21%
|
32.19
|
| Diluted NI Availto Com Stockholders |
|
-88.61
-95.57%
|
-45.31
+16.45%
|
-54.23
-7.74%
|
-50.33
|
| Other Taxes |
|
—
|
-13.74
-14.96%
|
-11.95
-21.68%
|
-9.82
|
| Rent Expense Supplemental |
|
—
|
—
|
—
|
0.41
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
131.44
-35.13%
|
202.63
+69.64%
|
119.45
-8.19%
|
130.10
|
| Current Assets |
|
118.66
-36.67%
|
187.37
+81.64%
|
103.15
-11.84%
|
117.01
|
| Cash Cash Equivalents And Short Term Investments |
|
85.11
-42.23%
|
147.33
+114.18%
|
68.79
-20.10%
|
86.10
|
| Cash And Cash Equivalents |
|
11.28
-90.71%
|
121.33
+76.38%
|
68.79
+3.69%
|
66.34
|
| Cash Equivalents |
|
0.00
-100.00%
|
64.74
+75.11%
|
36.97
+138.10%
|
15.53
|
| Cash Financial |
|
11.28
-80.07%
|
56.59
+77.85%
|
31.82
-37.38%
|
50.81
|
| Other Short Term Investments |
|
73.84
+183.94%
|
26.00
|
0.00
-100.00%
|
19.76
|
| Receivables |
|
24.61
-8.53%
|
26.91
+12.22%
|
23.98
+14.25%
|
20.99
|
| Accounts Receivable |
|
0.00
-100.00%
|
0.97
+235.17%
|
0.29
-73.81%
|
1.11
|
| Other Receivables |
|
22.01
-9.79%
|
24.40
+8.71%
|
22.44
|
—
|
| Taxes Receivable |
|
2.61
+69.29%
|
1.54
+23.69%
|
1.25
-93.74%
|
19.88
|
| Prepaid Assets |
|
8.93
-31.96%
|
13.12
+26.37%
|
10.38
+4.65%
|
9.92
|
| Total Non Current Assets |
|
12.78
-16.27%
|
15.27
-6.31%
|
16.30
+24.53%
|
13.09
|
| Net PPE |
|
1.75
-25.01%
|
2.33
-12.70%
|
2.67
+0.24%
|
2.66
|
| Gross PPE |
|
5.71
-16.73%
|
6.86
-4.35%
|
7.17
+8.00%
|
6.64
|
| Accumulated Depreciation |
|
-3.96
+12.46%
|
-4.53
-0.60%
|
-4.50
-13.21%
|
-3.97
|
| Machinery Furniture Equipment |
|
5.54
-12.63%
|
6.34
-1.44%
|
6.44
+6.66%
|
6.03
|
| Construction In Progress |
|
0.00
-100.00%
|
0.36
-1.66%
|
0.36
|
—
|
| Other Properties |
|
0.17
+6.37%
|
0.16
-57.57%
|
0.37
-38.61%
|
0.60
|
| Goodwill And Other Intangible Assets |
|
10.91
+12.42%
|
9.70
-6.18%
|
10.34
+2.61%
|
10.08
|
| Goodwill |
|
10.62
+13.09%
|
9.39
-5.90%
|
9.98
+2.98%
|
9.69
|
| Other Intangible Assets |
|
0.29
-7.69%
|
0.31
-13.81%
|
0.36
-6.52%
|
0.39
|
| Investments And Advances |
|
—
|
—
|
0.36
+5.26%
|
0.34
|
| Non Current Prepaid Assets |
|
0.13
-96.07%
|
3.23
-1.52%
|
3.28
|
0.00
|
| Total Liabilities Net Minority Interest |
|
69.14
+0.77%
|
68.61
-29.60%
|
97.45
-5.74%
|
103.38
|
| Current Liabilities |
|
13.61
-19.08%
|
16.82
-24.69%
|
22.34
-15.89%
|
26.56
|
| Payables And Accrued Expenses |
|
10.39
-19.78%
|
12.95
+4.44%
|
12.40
-18.87%
|
15.29
|
| Payables |
|
4.64
+1.09%
|
4.59
+0.81%
|
4.56
-11.25%
|
5.13
|
| Accounts Payable |
|
4.41
+19.26%
|
3.70
+10.42%
|
3.35
-13.17%
|
3.86
|
| Current Accrued Expenses |
|
5.75
-31.24%
|
8.36
+6.55%
|
7.85
-22.73%
|
10.15
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.96
-13.96%
|
3.44
+9.92%
|
3.13
|
—
|
| Total Tax Payable |
|
0.23
-73.88%
|
0.90
-25.83%
|
1.21
-5.48%
|
1.28
|
| Income Tax Payable |
|
0.04
-94.02%
|
0.65
+37.55%
|
0.47
-33.50%
|
0.71
|
| Current Debt And Capital Lease Obligation |
|
0.09
-23.93%
|
0.12
-48.68%
|
0.23
-57.76%
|
0.54
|
| Current Capital Lease Obligation |
|
0.09
-23.93%
|
0.12
-48.68%
|
0.23
-57.76%
|
0.54
|
| Current Deferred Liabilities |
|
0.17
-45.10%
|
0.31
-95.34%
|
6.57
-38.74%
|
10.73
|
| Current Deferred Revenue |
|
0.17
-45.10%
|
0.31
-95.34%
|
6.57
-38.74%
|
10.73
|
| Total Non Current Liabilities Net Minority Interest |
|
55.52
+7.21%
|
51.79
-31.06%
|
75.12
-2.23%
|
76.83
|
| Long Term Debt And Capital Lease Obligation |
|
0.07
|
0.00
-100.00%
|
0.12
|
0.00
|
| Long Term Capital Lease Obligation |
|
0.07
|
0.00
-100.00%
|
0.12
|
0.00
|
| Non Current Deferred Liabilities |
|
55.45
+7.07%
|
51.79
-30.95%
|
75.00
-2.38%
|
76.83
|
| Non Current Deferred Revenue |
|
55.45
+7.07%
|
51.79
-30.95%
|
75.00
-2.38%
|
76.83
|
| Stockholders Equity |
|
62.30
-53.51%
|
134.02
+509.39%
|
21.99
-17.66%
|
26.71
|
| Common Stock Equity |
|
62.30
-53.51%
|
134.02
+509.39%
|
21.99
-17.66%
|
26.71
|
| Capital Stock |
|
10.29
+0.02%
|
10.29
+16.29%
|
8.85
+35.63%
|
6.52
|
| Common Stock |
|
10.29
+0.02%
|
10.29
+16.29%
|
8.85
+35.63%
|
6.52
|
| Share Issued |
|
141.70
+0.02%
|
141.67
+19.21%
|
118.85
+10.24%
|
107.81
|
| Ordinary Shares Number |
|
141.70
+0.02%
|
141.67
+19.21%
|
118.85
+10.24%
|
107.81
|
| Additional Paid In Capital |
|
617.56
+1.31%
|
609.56
+33.74%
|
455.76
+62.42%
|
280.60
|
| Retained Earnings |
|
-562.57
-18.68%
|
-474.04
-9.76%
|
-431.89
-35.56%
|
-318.60
|
| Gains Losses Not Affecting Retained Earnings |
|
-2.98
+74.74%
|
-11.78
-9.85%
|
-10.72
-136.42%
|
29.45
|
| Other Equity Adjustments |
|
-2.98
+74.74%
|
-11.78
-9.85%
|
-10.72
-139.83%
|
26.92
|
| Total Equity Gross Minority Interest |
|
62.30
-53.51%
|
134.02
+509.39%
|
21.99
-17.66%
|
26.71
|
| Total Capitalization |
|
62.30
-53.51%
|
134.02
+509.39%
|
21.99
-17.66%
|
26.71
|
| Working Capital |
|
105.05
-38.41%
|
170.54
+111.03%
|
80.81
-10.66%
|
90.45
|
| Invested Capital |
|
62.30
-53.51%
|
134.02
+509.39%
|
21.99
-17.66%
|
26.71
|
| Total Debt |
|
0.16
+36.75%
|
0.12
-66.18%
|
0.35
-35.90%
|
0.54
|
| Capital Lease Obligations |
|
0.16
+36.75%
|
0.12
-66.18%
|
0.35
-35.90%
|
0.54
|
| Net Tangible Assets |
|
51.40
-58.66%
|
124.32
+967.12%
|
11.65
-29.95%
|
16.63
|
| Tangible Book Value |
|
51.40
-58.66%
|
124.32
+967.12%
|
11.65
-29.95%
|
16.63
|
| Available For Sale Securities |
|
—
|
—
|
0.36
+5.26%
|
0.34
|
| Foreign Currency Translation Adjustments |
|
—
|
—
|
2.49
-1.50%
|
2.52
|
| Investmentin Financial Assets |
|
—
|
—
|
0.36
+5.26%
|
0.34
|
| Other Equity Interest |
|
—
|
—
|
44.43
+54.61%
|
28.74
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-62.27
+7.94%
|
-67.64
-36.75%
|
-49.46
+13.29%
|
-57.04
|
| Cash Flow From Continuing Operating Activities |
|
-62.27
+7.94%
|
-67.64
-36.75%
|
-49.46
+13.29%
|
-57.04
|
| Net Income From Continuing Operations |
|
-88.61
-95.57%
|
-45.31
+16.45%
|
-54.23
-7.74%
|
-50.33
|
| Depreciation Amortization Depletion |
|
0.56
-6.41%
|
0.59
-4.51%
|
0.62
+4.19%
|
0.60
|
| Depreciation |
|
0.31
-7.14%
|
0.34
-8.94%
|
0.37
-2.64%
|
0.38
|
| Amortization Cash Flow |
|
0.24
-5.45%
|
0.26
+1.98%
|
0.25
+16.13%
|
0.22
|
| Depreciation And Amortization |
|
0.56
-6.41%
|
0.59
-4.51%
|
0.62
+4.19%
|
0.60
|
| Amortization Of Intangibles |
|
0.24
-5.45%
|
0.26
+1.98%
|
0.25
+16.13%
|
0.22
|
| Other Non Cash Items |
|
-3.48
+22.18%
|
-4.47
-148.03%
|
-1.80
-543.93%
|
-0.28
|
| Stock Based Compensation |
|
8.07
-50.49%
|
16.31
+0.20%
|
16.27
+28.28%
|
12.69
|
| Deferred Tax |
|
0.01
-98.70%
|
0.84
-11.61%
|
0.96
+38.95%
|
0.69
|
| Deferred Income Tax |
|
0.01
-98.70%
|
0.84
-11.61%
|
0.96
+38.95%
|
0.69
|
| Operating Gains Losses |
|
11.02
+527.04%
|
-2.58
-165.14%
|
3.96
+495.01%
|
-1.00
|
| Net Foreign Currency Exchange Gain Loss |
|
11.02
+527.04%
|
-2.58
-165.14%
|
3.96
+495.01%
|
-1.00
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
10.16
+130.76%
|
-33.02
-116.63%
|
-15.24
+21.41%
|
-19.40
|
| Change In Receivables |
|
5.07
+256.28%
|
-3.24
-7.64%
|
-3.01
+71.44%
|
-10.54
|
| Changes In Account Receivables |
|
1.02
+213.27%
|
-0.90
-330.61%
|
0.39
+154.22%
|
-0.72
|
| Change In Payables And Accrued Expense |
|
-4.08
-917.23%
|
0.50
+205.50%
|
-0.47
-123.37%
|
2.02
|
| Change In Payable |
|
-4.08
-917.23%
|
0.50
+205.50%
|
-0.47
-123.37%
|
2.02
|
| Change In Other Working Capital |
|
-0.33
+98.84%
|
-28.79
-178.85%
|
-10.32
-89.66%
|
-5.44
|
| Change In Other Current Assets |
|
9.67
+827.37%
|
-1.33
-5.39%
|
-1.26
+75.73%
|
-5.20
|
| Change In Other Current Liabilities |
|
-0.17
-1.82%
|
-0.17
+5.71%
|
-0.17
+25.53%
|
-0.23
|
| Investing Cash Flow |
|
-47.99
-118.48%
|
-21.97
-213.85%
|
19.29
+194.13%
|
-20.50
|
| Cash Flow From Continuing Investing Activities |
|
-47.99
-118.48%
|
-21.97
-213.85%
|
19.29
+194.13%
|
-20.50
|
| Net PPE Purchase And Sale |
|
-0.06
+73.93%
|
-0.21
-276.79%
|
-0.06
+67.63%
|
-0.17
|
| Purchase Of PPE |
|
-0.06
+73.93%
|
-0.21
-276.79%
|
-0.06
+67.63%
|
-0.17
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
-0.06
+73.93%
|
-0.21
-276.79%
|
-0.06
+89.72%
|
-0.55
|
| Net Investment Purchase And Sale |
|
-47.94
-120.35%
|
-21.75
-212.43%
|
19.35
+196.98%
|
-19.95
|
| Purchase Of Investment |
|
-166.41
-19.58%
|
-139.17
-440.01%
|
-25.77
-29.16%
|
-19.95
|
| Sale Of Investment |
|
118.48
+0.91%
|
117.41
+160.22%
|
45.12
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.37
|
| Purchase Of Intangibles |
|
—
|
0.00
|
0.00
+100.00%
|
-0.37
|
| Financing Cash Flow |
|
0.01
-99.99%
|
142.09
+344.90%
|
31.94
-39.26%
|
52.58
|
| Cash Flow From Continuing Financing Activities |
|
0.01
-99.99%
|
142.09
+344.90%
|
31.94
-39.26%
|
52.58
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
-0.22
+3.60%
|
-0.23
|
| Repayment Of Debt |
|
—
|
—
|
-0.22
+3.60%
|
-0.23
|
| Long Term Debt Payments |
|
—
|
—
|
-0.22
+3.60%
|
-0.23
|
| Net Long Term Debt Issuance |
|
—
|
—
|
-0.22
+3.60%
|
-0.23
|
| Net Common Stock Issuance |
|
0.01
-99.99%
|
142.09
+344.90%
|
31.94
-39.26%
|
52.58
|
| Changes In Cash |
|
-110.25
-310.07%
|
52.48
+2866.70%
|
1.77
+107.09%
|
-24.96
|
| Effect Of Exchange Rate Changes |
|
0.20
+225.00%
|
0.06
-91.99%
|
0.75
+109.23%
|
-8.12
|
| Beginning Cash Position |
|
121.33
+76.38%
|
68.79
+3.80%
|
66.27
-33.30%
|
99.35
|
| End Cash Position |
|
11.28
-90.71%
|
121.33
+76.38%
|
68.79
+3.80%
|
66.27
|
| Free Cash Flow |
|
-62.33
+8.14%
|
-67.85
-37.02%
|
-49.52
+14.01%
|
-57.59
|
| Income Tax Paid Supplemental Data |
|
0.64
+47.11%
|
0.43
-45.94%
|
0.80
|
0.00
|
| Common Stock Issuance |
|
0.01
-99.99%
|
142.09
+344.90%
|
31.94
-39.26%
|
52.58
|
| Interest Received CFI |
|
—
|
—
|
1.22
+4284.46%
|
0.03
|
| Issuance Of Capital Stock |
|
0.01
-99.99%
|
142.09
+344.90%
|
31.94
-39.26%
|
52.58
|
| Taxes Refund Paid |
|
—
|
—
|
7.91
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-05 View
- 8-K2026-03-05 View
- 42026-02-13 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42025-12-22 View
- 42025-12-22 View
- 8-K2025-12-22 View
- 8-K2025-12-15 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 8-K2025-10-23 View
- 8-K2025-08-14 View
- 10-Q2025-08-07 View
- 8-K2025-08-07 View
- 42025-08-04 View
- 42025-07-31 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|